Related Experiment Video
Updated: Mar 15, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
8.6K
[Clinical guidelines for infantile-onset Pompe disease]
S I Pascual-Pascual1, A Nascimento2, C M Fernandez-Llamazares3
1Hospital Universitario Materno Infantil La Paz, Madrid, Espana.
Revista De Neurologia
|September 8, 2016
Summary
Early diagnosis and enzyme replacement therapy are crucial for infantile-onset Pompe disease. Recommendations emphasize prompt treatment initiation for symptomatic infants upon clinical, enzymatic, and CRIM status confirmation.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Medicine
Background:
- Infantile-onset Pompe disease presents a severe, often fatal, short-term prognosis without timely intervention.
- Early diagnosis and prompt initiation of enzyme replacement therapy (ERT) are critical for improving outcomes.
- Multidisciplinary expert consensus is needed to guide management strategies.
Purpose of the Study:
- To review current scientific evidence on infantile-onset Pompe disease.
- To establish agreed-upon recommendations for diagnosis, treatment, and follow-up.
- To provide a clinical framework for managing this rare genetic disorder.
Main Methods:
- Systematic review of existing scientific literature.
- Multidisciplinary expert panel discussion and consensus building.
- Development of evidence-based clinical guidelines.
Main Results:
- Identification of key diagnostic criteria for infantile-onset Pompe disease.
- Establishment of treatment initiation thresholds for ERT.
- Consideration of cross-reactive immunological material (CRIM) status in treatment decisions.
Conclusions:
- Enzyme replacement therapy should be initiated in symptomatic patients with infantile-onset Pompe disease.
- Treatment decisions should be based on clinical presentation, enzymatic confirmation, and CRIM status.
- Standardized diagnostic and therapeutic protocols are essential for optimal patient care.
More Related Videos
Related Concept Videos
01:29Drug Dosing: Infants and Children
682
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
682
01:22Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
01:27Acute Pancreatitis I: Introduction
1.4K
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
1.4K
01:30Acute Pancreatitis II: Clinical Manifestations and Management
1.0K
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.0K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:20Inborn Errors of Metabolism
986
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
986